SOTHEMACAS:SOT +1.05%71 Interest Coverage is 30.76 as of Dec. 2025, which is 18% below its 10-year median of 37.53. GuruFocus rates CAS:SOT with a GF Score™ of 71/100 and a GF Value™ of MAD284.90 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 685 Drug Manufacturers companies, SOTHEMA ranks better than 65.11% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. SOTHEMA's
Operating Income
for the
six
months ended in Dec. 2025 was MAD376 Mil. SOTHEMA's Interest Expense for the
six
months ended in Dec. 2025 was MAD-12 Mil.
SOTHEMA's interest coverage for the quarter that ended in Dec. 2025 was 30.76.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for SOTHEMA's Interest Coverage or its related term are showing as below:
CAS:SOT'
s Interest Coverage Range Over the Past 10 Years
Min: 17.98 Med: 37.53 Max: 55.43
Current: 31.07
CAS:SOT's Interest Coverage is ranked better than 65.11% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs CAS:SOT: 31.07
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
SOTHEMA Interest Coverage Related Terms
SOTHEMA Interest Coverage Historical Data
* Premium members only.
The historical data trend for SOTHEMA's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CAS:SOT vs LLY, JNJ, ABBV: Interest Coverage Comparison
For the Drug Manufacturers - General subindustry, SOTHEMA's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SOTHEMA Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SOTHEMA's Interest Coverage distribution charts can be found below:
* The bar in red indicates where SOTHEMA's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOTHEMA (CAS:SOT) has a Interest Coverage of 30.76 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on SOTHEMA and its competitors. This is 18% below median its historical median of 37.53. Over the past decade, SOTHEMA's Interest Coverage has ranged from 17.98 to 55.43. According to the industry distribution chart, SOTHEMA ranks #239 out of 685 companies in the Drug Manufacturers industry, placing it in the top 34.9%.
Is SOTHEMA's Interest Coverage too high?
SOTHEMA's current Interest Coverage of 30.76 is 18% below median its 10-year median of 37.53. Over the past 10 years, this metric has ranged from a low of 17.98 to a high of 55.43. The Drug Manufacturers industry median Interest Coverage is 12.78. SOTHEMA's value of 30.76 is 140.7% above this industry median. Based on the distribution chart, SOTHEMA ranks #239 out of 685 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, SOTHEMA has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SOTHEMA's Interest Coverage compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, SOTHEMA ranks #239 out of 685 companies for Interest Coverage. This puts SOTHEMA in the upper half of its industry. The industry median Interest Coverage is 12.78. SOTHEMA's value of 30.76 is 140.7% above this benchmark. Historically, SOTHEMA's own Interest Coverage has ranged from 17.98 to 55.43 over the past decade. While the company's 10-year median is 37.53 vs. the industry median of 12.78, SOTHEMA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SOTHEMA's current Interest Coverage of 30.76 is 140.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on SOTHEMA and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SOTHEMA's current Interest Coverage is 30.76, which is 18% below median its own 10-year median of 37.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOTHEMA stock overvalued right now?
Based on GuruFocus' analysis, SOTHEMA (CAS:SOT) is currently considered Significantly Overvalued. The stock's GF Value™ is MAD284.90, compared to a current price of MAD379.95 — trading 33.4% above its estimated fair value. The current Interest Coverage is 30.76, which is 18% below median its 10-year median of 37.53 and 140.7% above the Drug Manufacturers industry median of 12.78. SOTHEMA's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For SOTHEMA (CAS:SOT), the current Interest Coverage is 30.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SOTHEMA (CAS:SOT) Overvalued in 2026?
Based on GuruFocus' analysis, SOTHEMA stock appears to be overvalued.
The current stock price of MAD379.95 is trading 33.4% above its estimated GF Value™ of MAD284.90.
GuruFocus considers SOTHEMA to be Significantly Overvalued.
Key valuation signals for CAS:SOT:
Interest Coverage: 30.76 (18% below median its 10-year median of 37.53)
GF Value™: MAD284.90 vs. price of MAD379.95 (33.4% above fair value)
Industry Position: 140.7% above the Drug Manufacturers median (#239 of 685)
No single metric tells the full story. See the CAS:SOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SOTHEMA engages in representation, purchase and sale of pharmaceutical, chemical, health-related, biological, veterinary, plant-based, cosmetic and scented products. The company sells its products in Morocco and overseas.
71GF Score
Get the complete analysis for CAS:SOT
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAS:SOT has been successfully added to your 
